104 results match your criteria: "USF Health Byrd Alzheimer's Institute[Affiliation]"

Accumulation of amyloid β (Aβ) and tau represent the two major pathological hallmarks of Alzheimer's disease (AD). Despite the critical importance of Aβ accumulation as an early event in AD pathogenesis, multiple lines of evidence indicate that tau is required to mediate Aβ-induced neurotoxic signals in neurons. We have previously shown that the scaffolding protein Ran-binding protein 9 (RanBP9), which is highly elevated in brains of AD and AD mouse models, both enhances Aβ production and mediates Aβ-induced neurotoxicity.

View Article and Find Full Text PDF

Cofilin-mediated Neuronal Apoptosis via p53 Translocation and PLD1 Regulation.

Sci Rep

September 2017

USF Health Byrd Alzheimer's Institute, Department of Molecular of Medicine, University of South Florida, Morsani College of Medicine, Tampa, FL, 33613, USA.

Amyloid β (Aβ) accumulation is an early event in the pathogenesis of Alzheimer's disease (AD), leading to mitochondrial and synaptic dysfunction, tau accumulation, and eventual neuronal death. While the p53 apoptotic pathway has clearly been associated with Aβ deposits and neuronal apoptosis, the critical upstream factors contributing to p53 activation in AD are not well understood. We have previously shown that cofilin activation plays a pivotal role in Aβ-induced mitochondrial and synaptic dysfunction.

View Article and Find Full Text PDF

Strain-dependence of the Angelman Syndrome phenotypes in Ube3a maternal deficiency mice.

Sci Rep

August 2017

Cain Foundation Laboratories, Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital and Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.

Angelman syndrome (AS) is a genetic neurodevelopmental disorder, most commonly caused by deletion or mutation of the maternal allele of the UBE3A gene, with behavioral phenotypes and seizures as key features. Currently no treatment is available, and therapeutics are often ineffective in controlling AS-associated seizures. Previous publications using the Ube3a maternal deletion model have shown behavioral and seizure susceptibility phenotypes, however findings have been variable and merit characterization of electroencephalographic (EEG) activity.

View Article and Find Full Text PDF
Article Synopsis
  • * Our research uncovered three significant variants: a protective variant in the PLCG2 gene and risk variants in ABI3 and TREM2, known for their roles in Alzheimer's susceptibility.
  • * The findings emphasize the importance of microglia, immune cells in the brain, suggesting that their genetic variations may contribute directly to the progression of Alzheimer's disease.
View Article and Find Full Text PDF

Although multiple CHCHD10 mutations are associated with the spectrum of familial and sporadic frontotemporal dementia-amyotrophic lateral sclerosis (FTD-ALS) diseases, neither the normal function of endogenous CHCHD10 nor its role in the pathological milieu (that is, TDP-43 pathology) of FTD/ALS have been investigated. In this study, we made a series of observations utilizing Caenorhabditis elegans models, mammalian cell lines, primary neurons and mouse brains, demonstrating that CHCHD10 normally exerts a protective role in mitochondrial and synaptic integrity as well as in the retention of nuclear TDP-43, whereas FTD/ALS-associated mutations (R15L and S59L) exhibit loss of function phenotypes in C. elegans genetic complementation assays and dominant negative activities in mammalian systems, resulting in mitochondrial/synaptic damage and cytoplasmic TDP-43 accumulation.

View Article and Find Full Text PDF

It is widely accepted that amyloid β (Aβ) generated from amyloid precursor protein (APP) oligomerizes and fibrillizes to form neuritic plaques in Alzheimer's disease (AD), yet little is known about the contribution of APP to intracellular signaling events preceding AD pathogenesis. The data presented here demonstrate that APP expression and neuronal exposure to oligomeric Aβ42 enhance Ras/ERK signaling cascade and glycogen synthase kinase 3 (GSK-3) activation. We find that RNA interference (RNAi)-directed knockdown of APP in B103 rat neuroblastoma cells expressing APP inhibits Ras-ERK signaling and GSK-3 activation, indicating that APP acts upstream of these signal transduction events.

View Article and Find Full Text PDF

Adding Recognition Discriminability Index to the Delayed Recall Is Useful to Predict Conversion from Mild Cognitive Impairment to Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative.

Front Aging Neurosci

March 2017

Author Affiliations: UC San Francisco; University of Southern California; UC San Francisco University of Southern California Mayo Clinic, Rochester Mayo Clinic, Rochester; UC Berkeley; U Pennsylvania; USC; UC Davis; Brigham and Women's Hospital/Harvard Medical School Indiana University Washington University St. Louis University of Pennsylvania; Prevent Alzheimer's Disease 2020 (Chair) Siemens; Alzheimer's Association University of Pittsburgh Washington University St. Louis Cornell University; Albert Einstein College of Medicine of Yeshiva University; AD Drug Discovery Foundation; Acumen Pharmaceuticals; Washington University St. Louis; Northwestern University; National Institute of Mental Health; Brown University; Eli Lilly (Chair); BWH/HMS (Chair); University of Washington (Chair); Mayo Clinic, Rochester (Core PI) University of Southern California; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC Davis (Core PI); UC Davis; UC San Diego; Mayo Clinic, Rochester (Core PI); Mayo Clinic, Rochester; University of London; UCLA School of Medicine; UCSF MRI; UC Davis; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; UC Berkeley (Core PI); University of Michigan; University of Utah; Banner Alzheimer's Institute; Banner Alzheimer's Institute; University of Pittsburgh; UC Berkeley; Washington University St. Louis; Washington University St. Louis; Washington University St. Louis; Washington University St. Louis; UPenn School of Medicine; UPenn School of Medicine; UPenn School of Medicine; UPenn School of Medicine; UPenn School of Medicine; USC (Core PI); USC; USC; Indiana University; Indiana University; UC Irvine; Indiana University; Indiana University; Indiana University; Indiana University; UC San Francisco; UC San Diego; Prevent Alzheimer's Disease 2020; UC San Diego; National Institute on Aging; UC San Francisco; Brown University; National Institute of Mental Health; Cornell University; Johns Hopkins University; Richard Frank Consulting; Prevent Alzheimer's Disease 2020; National Institute on Aging; Oregon Health & Science University; University of Southern California; University of California - San Diego; University of Michigan; Mayo Clinic, Rochester; Baylor College of Medicine; Columbia University Medical Center; Washington University, St. Louis; University of Alabama - Birmingham; Mount Sinai School of Medicine; Rush University Medical Center; Wien Center; Johns Hopkins University; New York University; Duke University Medical Center; University of Pennsylvania; University of Kentucky; University of Pittsburgh; University of Rochester Medical Center; University of California, Irvine; University of Texas Southwestern Medical School; Emory University; University of Kansas, Medical Center; University of California, Los Angeles; Mayo Clinic, Jacksonville; Indiana University; Yale University School of Medicine; McGill Univ., Montreal-Jewish General Hospital; Sunnybrook Health Sciences, Ontario; U.B.C. Clinic for AD & Related Disorders; Cognitive Neurology - St. Joseph's, Ontario; Cleveland Clinic Lou Ruvo Center for Brain Health; Northwestern University; Premiere Research Inst (Palm Beach Neurology); Georgetown University Medical Center; Brigham and Women's Hospital; Stanford University; Banner Sun Health Research Institute; Boston University; Howard University; Case Western Reserve University; University of California, Davis - Sacramento; Neurological Care of CNY; Parkwood Hospital; University of Wisconsin; University of California, Irvine - BIC; Banner Alzheimer's Institute; Dent Neurologic Institute; Ohio State University; Albany Medical College; Hartford Hospital, Olin Neuropsychiatry Research Center; Dartmouth-Hitchcock Medical Center; Wake Forest University Health Sciences; Rhode Island Hospital; Butler Hospital; UC San Francisco; Medical University South Carolina; St. Joseph's Health Care; Nathan Kline Institute; University of Iowa College of Medicine; Cornell University; University of South Florida: USF Health Byrd Alzheimer's Institute; University of California, San Francisco; University of Southern California; UC San Francisco; University of Southern California; Mayo Clinic, Rochester; Brigham and Women's Hospital/ Harvard Medical School; UC Davis; Mayo Clinic, Rochester; UC Berkeley; Washington University St. Louis; Indiana University; Perelman School of Medicine, UPenn; USC; Perelman School of Medicine, University of Pennsylvania; UC San Francisco; Rehabilitation Institute of Chicago, Feinberg School of Medicine, Northwestern University; BWH/HMS (Chair); University of Washington (Chair); Core PI; Mayo Clinic, Rochester (Core PI); University of Southern California; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC San Diego; UC San Francisco; UC San Francisco; UC San Francisco; UC Davis (Core PI); UC San Diego; Mayo Clinic, Rochester (Core PI); Mayo Clinic, Rochester; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; UC Berkeley (Core PI); University of Michigan; University of Utah; Banner Alzheimer's Institute; Banner Alzheimer's Institute; UC Berkeley; Washington University St. Louis; Washington University St. Louis; Washington University St. Louis; Perelman School of Medicine, UPenn; Perelman School of Medicine, UPenn; Perelman School of Medicine, UPenn; Perelman School of Medicine, UPenn; Perelman School of Medicine, UPenn; USC (Core PI); USC; USC; Indiana University; Indiana University; UC Irvine; Indiana University; Indiana University; Indiana University; Indiana University; UC San Francisco; Department of Defense (retired); University of Southern California; University of California, San Diego; Columbia University Medical Center; Rush University Medical Center; Wien Center; Duke University Medical Center; University of Rochester Medical Center; University of California, Irvine; Medical University South Carolina; Premiere Research Inst (Palm Beach Neurology); University of California, San Francisco; Georgetown University Medical Center; Brigham and Women's Hospital; Banner Sun Health Research Institute; Howard University; University of Wisconsin; University of Washington; Stanford University; Cornell University.

Ongoing research is focusing on the identification of those individuals with mild cognitive impairment (MCI) who are most likely to convert to Alzheimer's disease (AD). We investigated whether recognition memory tasks in combination with delayed recall measure of episodic memory and CSF biomarkers can predict MCI to AD conversion at 24-month follow-up. A total of 397 amnestic-MCI subjects from Alzheimer's disease Neuroimaging Initiative were included.

View Article and Find Full Text PDF

Effects of the synthetic neurosteroid ganaxolone on seizure activity and behavioral deficits in an Angelman syndrome mouse model.

Neuropharmacology

April 2017

USF Health Byrd Alzheimer's Institute, Tampa, FL, USA; Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL, USA. Electronic address:

Angelman syndrome (AS) is a rare neurogenetic disorder characterized by severe developmental delay, motor impairments, and epilepsy. GABAergic dysfunction is believed to contribute to many of the phenotypic deficits seen in AS. We hypothesized that restoration of inhibitory tone mediated by extrasynaptic GABA receptors could provide therapeutic benefit.

View Article and Find Full Text PDF

Potential Use of Flavopiridol in Treatment of Chronic Diseases.

Adv Exp Med Biol

July 2017

Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, 33612, USA.

This chapter describes the potential use of flavopiridol, a CDK inhibitor with anti-inflammatory and anti-proliferative activities, in the treatment of various chronic diseases. Flavopiridol arrests cell cycle progression in the G1 or G2 phase by inhibiting the kinase activities of CDK1, CDK2, CDK4/6, and CDK7. Additionally, it binds tightly to CDK9, a component of the P-TEFb complex (CDK9/cyclin T), and interferes with RNA polymerase II activation and associated transcription.

View Article and Find Full Text PDF

Ketone ester supplementation attenuates seizure activity, and improves behavior and hippocampal synaptic plasticity in an Angelman syndrome mouse model.

Neurobiol Dis

December 2016

USF Health Byrd Alzheimer's Institute, Tampa, FL 33613, United States; Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL 33620, United States. Electronic address:

Angelman syndrome (AS) is a rare genetic and neurological disorder presenting with seizures, developmental delay, ataxia, and lack of speech. Previous studies have indicated that oxidative stress-dependent metabolic dysfunction may underlie the phenotypic deficits reported in the AS mouse model. While the ketogenic diet (KD) has been used to protect against oxidative stress and has successfully treated refractory epilepsy in AS case studies, issues arise due to its strict adherence requirements, in addition to selective eating habits and weight issues reported in patients with AS.

View Article and Find Full Text PDF

Targeting innate immunity for neurodegenerative disorders of the central nervous system.

J Neurochem

September 2016

Sanders-Brown Center on Aging, Spinal Cord and Brain Injury Research Center, and Department of Anatomy and Neurobiology, University of Kentucky, Lexington, KY, USA.

Neuroinflammation is critically involved in numerous neurodegenerative diseases, and key signaling steps of innate immune activation hence represent promising therapeutic targets. This mini review series originated from the 4th Venusberg Meeting on Neuroinflammation held in Bonn, Germany, 7-9th May 2015, presenting updates on innate immunity in acute brain injury and chronic neurodegenerative disorders, such as traumatic brain injury and Alzheimer disease, on the role of astrocytes and microglia, as well as technical developments that may help elucidate neuroinflammatory mechanisms and establish clinical relevance. In this meeting report, a brief overview of physiological and pathological microglia morphology is followed by a synopsis on PGE2 receptors, insights into the role of arginine metabolism and further relevant aspects of neuroinflammation in various clinical settings, and concluded by a presentation of technical challenges and solutions when working with microglia and astrocyte cultures.

View Article and Find Full Text PDF

Amyloid Precursor Protein (APP) is regulated in a mitosis-specific manner and plays a role in proliferative signaling in cells. Though APP-derived Aβ generation has a well-established role in neurodegeneration, the mechanistic role of APP in this process is not fully understood. Here, we performed an unbiased, comprehensive analysis of the phosphoproteome signature in APP-null neuroblastoma cells (B103) compared to those expressing APP-695 isoform (B103-695) to determine if APP expression affects protein phosphorylation.

View Article and Find Full Text PDF

Transcription factor Sp1 inhibition, memory, and cytokines in a mouse model of Alzheimer's disease.

Am J Neurodegener Dis

January 2016

Department of Cellular and Molecular Biology, USFTampa, FL 33620; Current Address: NeuroEM Therapeutics, Inc.Phoenix, AZ 85022.

Transcription factors are involved to varying extents in the health and survival of neurons in the brain and a better understanding of their roles with respect to the pathogenesis of Alzheimer's disease (AD) could lead to the development of additional treatment strategies. Sp1 is a transcription factor that responds to inflammatory signals occurring in the AD brain. It is known to regulate genes with demonstrated importance in AD, and we have previously found it upregulated in the AD brain and in brains of transgenic AD model mice.

View Article and Find Full Text PDF

Cortical auditory evoked responses of older adults with and without probable mild cognitive impairment.

Clin Neurophysiol

February 2016

Department of Communication Sciences and Disorders, University of South Florida, Tampa, FL, USA; School of Aging Studies, University of South Florida, Tampa, FL, USA; USF Health Byrd Alzheimer's Institute, University of South Florida, Tampa, FL, USA.

Objective: Hearing loss has been well-documented as a risk factor for cognitive impairment, but the simple presence of hearing loss is not a sufficient predictor of cognitive decline. Although auditory behavioral research has not revealed an effective indicator of early cognitive impairment, a limited number of studies using cortical auditory evoked potentials (CAEPs) have shown promising evidence of an auditory neurophysiological indicator of early-stage cognitive impairment. The purpose of this study was to examine the P1-N1-P2 complex for indicators of cognitive impairment.

View Article and Find Full Text PDF

Both wild-type and mutated beta-amyloid (Aβ) peptides can elicit an immune response when delivered subcutaneously. However, only mutated forms of Aβ can sensitize dendritic cells when administered intravenously or intraperitoneally. To understand the role of mutation and delivery routes in creating immune responses, and the function of dendritic cells as therapeutic agents, we used fluorescent-conjugated WT Aβ1-40 (WT40) and artificially mutated Aβ1-40 (22W40) peptides to treat dendritic and Langerhans cells from young and/or old mice at different time points.

View Article and Find Full Text PDF

Pancreatic cancer shows a strong correlation with smoking and the current therapeutic strategies have been relatively ineffective in improving the survival of patients. Efforts have been made over the past many years to understand the molecular events that drive the initiation and progression of pancreatic cancer, especially in the context of smoking. It has become clear that components of tobacco smoke not only initiate these cancers, especially pancreatic ductal adenocarcinomas (PDACs) through their mutagenic properties, but can also promote the growth and metastasis of these tumors by stimulating cell proliferation, angiogenesis, invasion and epithelial-mesenchymal transition.

View Article and Find Full Text PDF

Calorie restriction (CR) has been shown to increase lifespan and delay aging phenotypes in many diverse eukaryotic species. In mouse models of Alzheimer's disease (AD), CR has been shown to decrease amyloid-beta and hyperphosphorylated tau levels and preserve cognitive function. Overexpression of human mutant tau protein has been shown to induce deficits in mitochondrial electron transport chain complex I activity.

View Article and Find Full Text PDF

An optimized InCell Western screening technique identifies hexachlorophene as a novel potent TDP43 targeting drug.

J Biotechnol

August 2015

Department of Pharmaceutical Science, College of Pharmacy, USF Health Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33613, USA. Electronic address:

TAR DNA binding protein (TDP43) is a DNA- and RNA-binding protein that is implicated in several neurodegenerative disorders termed as "TDP43 proteinopathies" including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and fronto-temporal lobe dementia (FTLD). We have developed an InCell Western (ICW) technique for screening TDP targeting drugs in 96 well plates. We tested 281 compounds and identified a novel compound hexachlorophene (referred to as B10) that showed potent reduction in TDP43 levels.

View Article and Find Full Text PDF

Background: HIV-infected long-term non-progressor (LTNP) subjects can prevent viral replication and may harbor useful information for the development of both antibody and active vaccination treatments. In this study we used LTNP sera to examine the epitopes presented to the gp160 protein, and from this procedure we hope to elucidate potential biomarkers pertaining to the level of resistance a patient may have in developing AIDS after infection with HIV. We used five clinical sera samples from LTNP patients to identify common epitopes by ELISA; peptides with high binding to sera were selected and analyzed for conservation among HIV clades.

View Article and Find Full Text PDF

The Reelin signaling pathway is implicated in processes controlling synaptic plasticity and hippocampus-dependent learning and memory. A single direct in vivo application of Reelin enhances long-term potentiation, increases dendritic spine density and improves associative and spatial learning and memory. Angelman syndrome (AS) is a neurological disorder that presents with an overall defect in synaptic function, including decreased long-term potentiation, reduced dendritic spine density, and deficits in learning and memory, making it an attractive model in which to examine the ability of Reelin to recover synaptic function and cognitive deficits.

View Article and Find Full Text PDF

Isoform-selective Genetic Inhibition of Constitutive Cytosolic Hsp70 Activity Promotes Client Tau Degradation Using an Altered Co-chaperone Complement.

J Biol Chem

May 2015

From the Department of Molecular Medicine, College of Medicine, USF Health Byrd Alzheimer's Institute, University of South Florida, Tampa, Florida 33613, James A. Haley Veteran's Hospital, Tampa, Florida 33612,

The constitutively expressed heat shock protein 70 kDa (Hsc70) is a major chaperone protein responsible for maintaining proteostasis, yet how its structure translates into functional decisions regarding client fate is still unclear. We previously showed that Hsc70 preserved aberrant Tau, but it remained unknown if selective inhibition of the activity of this Hsp70 isoform could facilitate Tau clearance. Using single point mutations in the nucleotide binding domain, we assessed the effect of several mutations on the functions of human Hsc70.

View Article and Find Full Text PDF

Immunostaining analysis of tissue cultured cells and tissue sections using phospho-Histone H3 (Serine 10) antibody.

Methods Mol Biol

December 2015

Department of Molecular Medicine, USF Health Byrd Alzheimer's Institute, University of South Florida, 4001 E Fletcher Ave, Tampa, 33613, FL, USA,

Post-translational modifications of histones play an important role in regulation of gene expression through condensation and decondensation of chromatin structure. These modifications include acetylation, methylation, phosphorylation and ubiquitination. Phosphorylation on histones is associated with cellular responses such as DNA damage, transcription, chromatin compaction and mitosis or meiosis.

View Article and Find Full Text PDF

Molecular pathways underlying the neurotoxicity and production of amyloid β protein (Aβ) represent potentially promising therapeutic targets for Alzheimer's disease (AD). We recently found that overexpression of the scaffolding protein RanBP9 increases Aβ production in cell lines and in transgenic mice while promoting cofilin activation and mitochondrial dysfunction. Translocation of cofilin to mitochondria and induction of cofilin-actin pathology require the activation/dephosphorylation of cofilin by Slingshot homolog 1 (SSH1) and cysteine oxidation of cofilin.

View Article and Find Full Text PDF

The accumulation of amyloid-β protein (Aβ) is an early event associated with synaptic and mitochondrial damage in Alzheimer's disease (AD). Recent studies have implicated the filamentous actin (F-actin) severing protein, Cofilin, in synaptic remodeling, mitochondrial dysfunction, and AD pathogenesis. However, whether Cofilin is an essential component of the AD pathogenic process and how Aβ impinges its signals to Cofilin from the neuronal surface are unknown.

View Article and Find Full Text PDF

Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.

PLoS One

January 2016

Center of Excellence for Aging & Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, Tampa, Florida, 33612, United States of America; Molecular Pharmacology and Physiology, University of South Florida Morsani College of Medicine, Tampa, Florida, 33612, United States of America; James A. Haley Veterans Affairs Hospital, Research Service, Tampa, Florida, 33612, United States of America.

The protein α-synuclein (α-Syn) has a central role in the pathogenesis of Parkinson's disease (PD) and immunotherapeutic approaches targeting this molecule have shown promising results. In this study, novel antibodies were generated against specific peptides from full length human α-Syn and evaluated for effectiveness in ameliorating α-Syn-induced cell death and behavioral deficits in an AAV-α-Syn expressing rat model of PD. Fisher 344 rats were injected with rAAV vector into the right substantia nigra (SN), while control rats received an AAV vector expressing green fluorescent protein (GFP).

View Article and Find Full Text PDF